A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms

Publisher: John Wiley & Sons Inc

E-ISSN: 1096-8652|93|2|277-285

ISSN: 0361-8609

Source: AMERICAN JOURNAL OF HEMATOLOGY, Vol.93, Iss.2, 2018-02, pp. : 277-285

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract